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Abstract
Purpose: Avoiding toxicities in radiotherapy requires the knowledge of tol-
erable organ doses. For new, experimental fractionation schemes (e.g. hy-
pofractionation) these are typically derived from traditional schedules using
the Biologically Effective Dose (BED) model. In this report we investigate the
difficulties of establishing mean dose tolerances that arise since the mean BED
depends on the entire spatial dose distribution, rather than on the dose level
alone.
Methods: A formula has been derived to establish mean physical dose con-
straints such that they are mean BED equivalent to a reference treatment
scheme. This formula constitutes a modified BED equation where the influ-
ence of the spatial dose distribution is summarized in a single parameter, the
dose shape factor. To quantify effects we analyzed 24 liver cancer patients for
whom both proton and photon IMRT treatment plans were available.
Results: The results show that the standard BED equation - neglecting the
spatial dose distribution - can overestimate mean dose tolerances for hypofrac-
tionated treatments by up to 20%. The shape difference between photon and
proton dose distributions can cause 30-40% differences in mean physical dose for
plans having identical mean BEDs. Converting hypofractionated, 5/15-fraction
proton doses to mean BED equivalent photon doses in traditional 35-fraction
regimens resulted in up to 10Gy higher doses than applying the standard BED
formula.
Conclusions: The dose shape effect should be accounted for to avoid overes-
timation of mean dose tolerances, particularly when estimating constraints for
hypofractionated regimens. Additionally, tolerances established for one treat-
ment modality cannot necessarily be applied to other modalities with drastically
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different dose distributions, such as proton therapy. Last, protons may only al-
low marginal (5-10%) dose escalation if a fraction-size adjusted organ mean
dose is constraining instead of a physical dose.
Keywords: BED, Normal Tissue Tolerance, Proton Therapy, IMRT, Mean
Dose Constraints.
1 Introduction
The safe use of radiotherapy requires the knowledge of radiation doses that healthy tissues can tolerate.
These dose tolerances are typically obtained from clinical data by correlating dose metrics with the
occurrence rates of radiation toxicities. Subsequently, they guide the selection of dose constraints in
treatment planning to limit the risk of radiation induced side effects. The most common constraints are
maximum dose, mean dose, Dose Volume Histogram (DVH) and generalized Equivalent Uniform Dose
(gEUD) constraints [1, 2, 3, 4, 5].
Since the beneficial effects of fractionated radiotherapy have been discovered early on [6, 7, 8, 9, 10, 11],
the vast majority of treatments have applied 25-35 fractions with 2 Gy dose per fraction, leading to total
target doses of 50 Gy to 70 Gy. This is referred to as the standard fractionation. Consequently, most dose
tolerances have been determined for these conventional fractionation schedules. Current trends towards
hypofractionation [12, 13, 14, 15] (i.e. the use of fewer fractions with higher dose per fraction) require
dose tolerances for such experimental regimens, too. Additionally, the spread of charged particle therapy
necessitates establishing dose tolerances for new treatment modalities as well.
Before routine clinical use, dose constraints for a new fractionation scheme (or modality) always have
to be validated by outcome data. However, in the initial design of clinical trials testing an experimental
treatment schedule, the Biologically Effective Dose (BED) [8, 10, 16, 17] model is often used to derive
dose tolerances from established fractionation schemes. The procedure for establishing maximum dose
constraints - where only a single dose level is considered - is familiar to practitioners [18, 5, 8, 17, 19,
20, 21]. Our paper focuses on the derivation of mean dose tolerances, where additional difficulties arise.
Specifically, we address 3 questions:
• How can mean dose constraints be established for new fractionation schemes using the BED model?
Mean organ doses are used to estimate normal tissue complications for several major treatment
sites (e.g. liver, lung [22, 23, 24, 25]). Therefore, the derivation of mean dose tolerances in new
(hypofractionated) treatment schedules directly affects their safety. Since the mean BED in an
organ depends not only on the mean physical dose, but also on the entire, typically inhomogeneous
dose distribution, this should be accounted for (Section 3.2).
• Can mean dose constraints established for one modality (e.g. 3DCRT or IMRT) be applied one-
to-one to other modalities (e.g. VMAT, protons)? In clinical trials investigating the efficacy of
proton treatments (vs. photons), dose escalation is often done based on the mean physical dose
of adjacent healthy organs [26]. However, proton dose distributions are significantly different from
photon distributions: for the same mean dose, protons typically emphasize the high dose region
and reduce the low dose bath. Consequently, proton plans usually have higher mean BED for
the same mean dose, making it important to study the potential effects of the spatial differences
(Section 3.3).
• What is the dose escalation potential of proton therapy vs. photons for the same normal tissue
complication probability (NTCP)? Current proton therapy plans often have larger margins around
the target structures than state-of-the-art IMRT plans, mainly due to uncertainties in proton range
(e.g. a typical 3.5% range uncertainty can translate to a distal margin up to 1 cm [27]). At the
same time, adjusting for fractionation with the BED model effects high dose values more than low
doses. Consequently the dose escalation potential of proton therapy, as assessed from gEUD based
NTCP-models, is expected to decrease when the physical dose is adjusted for fractionation. With
the spread of particle therapy treatments aimed at increasing target doses these effects should be
investigated (Section 3.5).
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2 Methods and Materials
2.1 Biologically Effective Dose Model
To describe fractionation effects we use the standard BED model [8, 10, 16, 17], stating that the biological
dose is
BED = Nd
(
1 + d
α/β
)
= D
(
1 + D
Nα/β
)
, (1)
where D = Nd is the total dose given in N fractions with dose per fraction d, and α/β represents
the fractionation sensitivity of the tissue. Equation 1 is frequently used to guide the derivation of iso-
effective doses in experimental fractionation schemes based on established schemes [5, 8, 17, 19, 20]. If
an organ-at-risk (OAR) can tolerate a dose Dref in Nref fractions, the tolerance in a new scheme with
Nnew fractions can be obtained by equating the BEDs for the two regimens, i.e. solving
Dnew
(
1 + Dnew
Nnewα/β
)
= Dref
(
1 + Dref
Nrefα/β
)
(2)
for the new dose tolerance Dnew. The solution is
Dnew =
1
2
[√
(Nnewα/β)2 + 4Dref
(
Nnewα/β +Dref
Nnew
Nref
)
−Nnewα/β
]
. (3)
Equation 3 is equivalent to the well-known Withers iso-effect formula [21], except here we use the to-
tal dose and the number of fractions as variables instead of the total dose and the dose per fraction.
Traditionally, the Withers formula has been used to derive maximum dose constraints for serial OARs
located within or near the target volume. In this case the reference dose Dref is given by the prescription
dose and it is assumed that the OAR receives the same dose. Therefore, as also pointed out in [18], this
approach implicitly assumes that the iso-effect is calculated for a serial organ receiving the same dose in
the same number of fractions as the tumor.
2.2 Mean BED vs. BED of the Mean
Not every OAR can however be considered serial and radiation induced side effects not only depend
on the maximum dose: for different organs various Dose Volume Histogram (DVH) metrics were found
to be predictive of normal tissue damage [28, 5]. Consequently, NTCP models typically include DVH
reduction methods (e.g. gEUD or effective volume) using a volume parameter n to describe the "volume
effect" of organs [29, 1, 30], with n being close to zero when the effect is small (in serial organs) and
around unity when the effect is large (in parallel organs). The exact value of the volume parameter is
subject to considerable uncertainty, however, for several OARs it has been found to be sufficiently close
to 1 [31, 24] such that simply the mean dose could be considered predictive of radiation damage.
In clinical radiotherapy practice therefore mean dose tolerances are still commonly employed in treat-
ment planning for organs with parallel structure (e.g. lung, liver [22, 23, 24]). Hence it is desirable to be
able to use the BED model to derive mean dose tolerances in experimental fractionation schemes from
established ones. The difficulty arises from the fact that the true mean BED of an inhomogeneous dose
distribution is not the same as the BED corresponding to the mean physical dose of that distribution.
Introducing the voxel doses Di (and for later use the dose vector D = (D1, D2, ..., DM ), where M is the
number of voxels), the mean BED can be calculated using the mean physical dose Dmean = 1/M
M∑
i=1
Di
as:
BEDmean =
1
M
M∑
i=1
BEDi =
1
M
M∑
i=1
Di (1 +Di/ (Nα/β)) = Dmean
(
1 + 1
Dmean
1
M
∑M
i=1D
2
i
Nα/β
)
= Dmean
1 + Dmean
Nα/β
1
M
∑M
i=1D
2
i(
1
M
∑M
i=1Di
)2
 = Dmean
1 + Dmean
Nα/β
M
∑M
i=1D
2
i(∑M
i=1Di
)2
 . (4)
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Equation 4 reveals that the mean BED is not only defined by the mean physical dose and the fractionation
scheme, but also by the spatial distribution of the dose. The effect of the dose distribution can be
summarized by a single dimensionless parameter, the dose shape factor
ϕ = M
∑M
i=1D
2
i(∑M
i=1Di
)2 . (5)
The appendix of [18] gives a practically identical derivation for Equation 4, but calls the dose shape factor
of Equation 5 the "dose heterogeneity factor", and implicitly [32] also makes use of this formulation. In
essence, the dose shape factor provides a practical, straightforward insight into the effect of the dose
distribution on the mean BED (however, it "only" accounts for the shape, and not for example for organ
structure or heterogeneities in radiobiological properties, etc.).
Using Equation 5 allows the mean BED to be calculated as
BEDmean = Dmean
(
1 + Dmean
Nα/β
ϕ
)
.
Therefore, to obtain mean dose tolerances Dnew for a treatment modality characterized by ϕnew, based
on a reference modality with dose shape factor ϕref and mean dose tolerance Dref, one has to solve
Dnew
(
1 + Dnew
Nnewα/β
ϕnew
)
= Dref
(
1 + Dref
Nrefα/β
ϕref
)
(6)
for Dnew (instead of Equation 2). The solution is
Dnew =
1
2
√(Nnewα/β
ϕnew
)2
+ 4Dref
(
Nnewα/β
ϕnew
+Dref
ϕref
ϕnew
Nnew
Nref
)
− Nnewα/β
ϕnew
 . (7)
There are 3 important aspects regarding the impact of the dose shape factor on the mean BED:
• The dose shape factor is never smaller than unity, i.e. ϕ ≥ 1. Therefore the mean BED is always
bigger than the simple BED equivalent of the mean physical dose (ϕ = 1 only holds for completely
homogeneous distribution).
• The dose shape factor and the mean BED both increase with the variance of the spatial dose
distribution1 [18]. This can be seen if we use the variance of the dose distribution, var (D) =
1/M
∑M
i=1 (Di −Dmean)2, to rewrite Equation 5 as
ϕ = 1
Dmean
∑M
i=1D
2
i∑M
i=1Di
= 1
Dmean
(
Dmean +
var (D)
Dmean
)
.
Higher variance in the dose distribution therefore leads to higher ϕ and mean BED as well.
• Two treatments with identical mean physical doses D1mean = D2mean and fractionation schemes
N1 = N2 are not necessarily equivalent in terms of mean BED. BED1mean = BED2mean only holds
if the spatial distributions are also similar, i.e. if ϕ1 = ϕ2.
2.3 Consistency with gEUD Based NTCP Modelling
Requiring the equivalence of the mean BEDs (Equation 6) is consistent with typical NTCP modelling.
This is presented in details in Section A. The main result is that for a majority of NTCP models -
including the popular Lyman-Kutcher-Burman model (see Section B) - two dose distributions have the
same NTCP if they have identical "generalized Equivalent Uniform Biologically Effective Doses" [33, 18],
i.e. if
gEUBEDn (Dnew, Nnew, α/β) = gEUBEDn (Dref, Nref, α/β) . (8)
1Temporal variance similarly increases the mean BED, see Section 1.1 of the Supplementary Materials (SM).
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The "generalized Equivalent Uniform Biologically Effective Dose", denoted by gEUBEDn (D, N, α/β) is
simply a generalized Equivalent Uniform Dose calculation gEUDn (BED (D, N, α/β)) based on the BED
distribution BED (D, N, α/β) corresponding to the physical dose distribution D given in N fractions,
with fractionation sensitivity α/β, using n as the volume parameter:
gEUBEDn (D, N, α/β) =
(
1
M
M∑
i=1
BED1/ni
)n
=
[
1
M
M∑
i=1
(
Di
(
1 + Di
Nα/β
))1/n]n
. (9)
For n = 1 the gEUD is identical to the arithmetic mean and Equation 8 simplifies to Equation 6, which
can be solved analytically to yield Equation 7.
We specifically use Equation 8 to study iso-toxic dose escalation. To calculate how a dose distribution
Dnew can be scaled to a distribution f · Dnew such that it leads to the same NTCP as the reference
distribution Dref,
gEUBEDn (f ·Dnew, Nnew, α/β) = gEUBEDn (Dref, Nref, α/β)
has to hold. Filling in the formula for calculating the gEUBEDs (Equation 9) for the two dose distribu-
tions leads to 1
M
M∑
i=1
(
f ·Dnew,i
(
1 + f ·Dnew,i
Nnewα/β
))1/nn =
 1
M
M∑
i=1
(
Dref,i
(
1 + Dref,i
Nrefα/β
))1/nn . (10)
For given dose distributions (Dnew, Dref), fraction numbers (Nnew, Nref) and chosen n and α/β values,
the only unknown is the scaling factor f . Hence numerically solving Equation 10 for f provides a general
method for iso-NTCP based dose escalation.
2.4 Using BED Formulas
The effects of the dose shape factor on the mean BED - detailed in Section 2.2 - have important conse-
quences when iso-effective (i.e. iso-toxic) mean doses are calculated between fractionation schemes and
between modalities. We consider 3 scenarios corresponding to special cases of Equation 6:
• Case 1 demonstrates the effects of the dose shape when doses are calculated between fractionation
schemes (Nnew 6= Nref) for the same irradiation modality (ϕnew = ϕref, Section 3.2).
• Case 2 compares different modalities (ϕnew 6= ϕref) for the same fractionation (Nnew = Nref,
Section 3.3). We consider photons as the reference (with ϕref being the photon dose shape factor)
and calculate the mean dose in photon plans (Dref = Dnew + ∆D) that is mean BED equivalent
with proton mean doses Dnew (with ϕnew being the proton dose shape factor). The difference
∆D = Dref − Dnew represents an effective dose difference resulting from the shape difference
∆ϕ = ϕnew − ϕref.
• Case 3 uses Equation 6 to relate one treatment with dose shape ϕnew, Nnew fractions, and mean dose
Dnew to another treatment characterized by ϕref, Nref fractions, and Dref (Section 3.4). Specifically,
for a hypofractionated proton treatment with mean dose Dnew and dose shape factor ϕnew (Nnew =
5 or 15), we calculate the mean dose Dref in a conventionally fractionated (Nref = 35) photon plan
with dose shape factor ϕref, that would be mean BED equivalent.
Additionally, we study the dose escalation potential of proton therapy vs. photon therapy as assessed
by iso-NTCP based dose escalation:
• Case 4 compares the given proton plansDproton (which were delivered to the patients inN = 5 or 15
fractions) to the planned photon plans Dphoton, when the photon plans are scaled such that they
lead to the same NTCP as their proton counterpart. We use Equation 10 to search for a scale
factor f , such that the scaled photon dose distribution fDphoton in N fractions gives the same
gEUBEDn as protons. The dose escalation potential of protons is
DGTVproton
fDGTVphoton
, which is the ratio
5
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of the average GTV doses in the (delivered) proton dose distribution and the scaled (planned)
photon dose distribution. The ratio will clearly depend on the chosen volume parameter n and the
fractionation sensitivity α/β, however, not on the fraction size fs used to adjust for fractionation
(see Section A). For α/β = ∞ the ratio signals the dose escalation potential based purely on
physical dose, whereas for α/β < ∞ the dose escalation also takes into account the effects of
fractionation. In order to estimate the dose escalation potential for standard fractionation as well,
we perform the same calculations by considering scaled proton plans delivering 70 Gy to the GTV
in N = 35 fractions as the reference. Therefore, we also determine the scale factors f such that the
scaled photon dose distributions fDphoton in N = 35 fractions give the same gEUBEDn values as
the scaled proton dose distributions 70 Gy/DGTVproton ·Dproton in N = 35 fractions, yielding the dose
escalation potential of protons for standard fractionation as 70 Gy
fDGTVphoton
.
Throughout the paper relative biological effectiveness (RBE) is taken into account by adjusting proton
doses with RBEproton = 1.1. BED calculations are done subsequent to the RBE adjustment using Equa-
tion 1 and all presented proton dose values are the RBE corrected doses Dproton = RBEproton · D˜proton.
In [34] Dale and Jones introduced a modified BED formulation that allows the direct incorporation of
RBE effects. Our theoretical models can be generalized accordingly, and the differences between the two
approaches are relatively small (for a detailed discussion and a comparison of the results see Section C).
2.5 Patient Data
We analyzed 24 liver cancer patients with varying tumor size, location and recurrence status. Patients
underwent a 2 day CT simulation to assess internal motion and reproducibility. Plans were created
using mid-ventilation CT (30% phase) where the tumor volume was derived from arterial/venous phase
contrast CT scan fused to the planning CT.
All patients were treated with passively scattered protons in 5 or 15 fractions, with prescription doses
of 40 Gy or 50 Gy for the former; and between 45 Gy to 67.5 Gy for the latter schedule. Proton plans
incorporated aperture expansion and compensator smearing based on measured internal organ motion,
utilizing 2-3 fields per plan. For research purposes, IMRT plans were also made for the patients, using the
same target volumes, 7-10 treatment fields, and standard clinical planning procedures. Since the passively
scattered protons were used for treatment and liver motion was considerable, proton plans typically
employed larger margins than their photon counterparts to avoid potential loss of target coverage. For
all proton and photon plans the mean dose and the dose variance were calculated for the healthy liver
(liver minus the Clinical Target Volume), and subsequently the dose shape factors were determined. For
analysing the dose variance in Section 3.1 and the example patient in Section 3.3.1, the IMRT plans
were scaled such that the healthy liver mean physical dose matched that of their proton counterpart.
For the calculations of case 4 (Section 3.5) IMRT plans were scaled according to Equation 10, such that
the healthy liver gEUBEDs were identical to those of the proton plans for a range of volume parameters
n ∈ [0, 1.2] and three different fractionation sensitivity values of α/β ∈ {2, 4,∞}Gy.
3 Results
3.1 Dose Variance and Dose Shape Factor of Proton and Photon Plans
Figure 1 gives an overview of the dose differences between proton and photon plans. There is a clear
distinction in terms of the dose variance (Figure 1a): proton plans have higher dose variance for the
same mean healthy liver dose. The distinction in terms of dose shape factor ϕ becomes apparent in
Figure 1b showing the dose shape factor as a function of the relative liver dose (i.e. the fraction of
the mean dose in the healthy liver and the GTV). Photon plans have smaller dose shape factors than
proton plans. The average dose shape factor across all photon plans is 2.2, whereas the average dose
shape factor for proton plans is 4.0. Furthermore, as shown in Figure 1b, there is a decreasing trend of
ϕ with the relative mean dose (for the fit results see Section 2 of the Supplementary Materials (SM)).
This is intuitive: lower relative mean dose signals better dose sparing, which inevitably leads to more
dose variation in the organ.
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Figure 1. Comparison of the photon and proton dose distributions in the healthy liver (liver minus CTV).
3.2 Calculating Iso-Effective Mean Doses in New Fractionation Schemes
(Case 1)
3.2.1 Analysis of Proton and Photon Plans
Figure 2 demonstrates the effects of the dose shape factor when iso-effective mean doses in new fractiona-
tion schemes are calculated for commonly used liver mean dose tolerances [5, 23, 31] and α/βLiver = 4 Gy.
First, we calculate the dose to be delivered in 5 fractions that is equivalent with 30 Gy in 35 fractions,
a widely applied mean dose constraint in standard fractionation (blue lines, Figure 2a). The traditional
BED formulation (Equation 3) yields an equivalent 5-fraction dose of 18.8 Gy (dashed line). In contrast,
when the calculation is done employing Equation 7 (using ϕref = ϕnew ≥ 1), the 5-fraction doses are
systematically lower (solid line). E.g. for a commonplace value of ϕ = 3 the equivalent dose is 15 Gy,
20% lower than 18.8 Gy. Second, we calculate the dose in 35 fractions that is equivalent to 17 Gy in 5
fractions (red lines). The standard BED formulation yields 26.5 Gy, whereas the mean BED equivalent
doses are up to 40% higher for realistic ϕ values.
Figure 2b quantifies this effect for clinical treatment plans. The healthy liver mean doses Dref in
the proton plans - delivered in 5 or 15 fractions - were converted to equivalent 35-fraction doses Dnew
(Nref = 5 or 15, Nnew = 35, ϕref = ϕnew corresponding to the proton dose shape factors), in order
to compare them to proton treatments with standard fractionation. The truly mean BED equivalent
35-fraction doses are systematically and significantly higher than what the traditional BED formulation
(Equation 3) suggests. Differences up to 8 Gy (+40%) can be observed. Moreover, while all plans seem
safe according to the simple BED model having 35-fraction mean doses below 30 Gy, for 1 patient the
mean BED equivalent mean dose is 5 Gy higher than the tolerance.
3.2.2 Analysis of the Protocol of a Phase II Randomized Trial for Hepatocellular Carci-
noma
In the NRG-GI003 cooperative group clinical trial protocol [26] (clinicaltrials.gov identifier NCT03186898,
currently recruiting patients) liver tolerances are given as prescription dose dependent values, separately
for 5- and 15-fraction treatments (shown in black in Table I). Assuming α/βTumor = 10 Gy, the pre-
scription dose levels in the 2 fractionation schemes (columns 1 and 2) are approximately iso-effective:
e.g. 50 Gy in 5 fractions and 67.5 Gy in 15 fractions both represent ≈ 100 Gy10 BED. The corresponding
tumor BED values (shown in blue, column 3) are monotonically decreasing with decreasing prescription
dose.
Columns 4 and 5 show the mean dose constraints for the healthy liver for 5 and 15 fractions, re-
spectively. Making the 4 dose tolerance pairs belonging to the same tumor BED levels BED equiva-
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Figure 2. Difference between taking into account vs. neglecting the effects of the dose distribution when
calculating iso-effective mean doses between fractionation schemes. Panel (a) presents a theoretical case
showing the mean doses that are BED equivalent to 2 clinically used liver mean dose constraints as a
function of the dose shape factor. Panel (b) highlights the BED equivalent liver mean doses using the
data from our patient cohort.
lent requires unrealistically low α/βeq ∈ [0.17, 1.14] Gy values (shown in red in Table I) if the simple
BED formula (Equation 2) is used. Furthermore, the resulting equivalent liver BED levels BEDeq vary
non-monotonically. Using a realistic α/βLiver = 4 Gy value in Equation 3 to calculate the 15-fraction
equivalent of 5-fraction tolerances yields doses (shown in yellow) 4 Gy to 6 Gy (more than 20%) below
the actual values. Consequently, the used liver tolerance values are not consistent with the traditional
BED formalism.
Table I. Mean liver tolerances for 5 and 15 fractions in the NRG-GI003 cooperative group clinical trial protocol.
Calculated tumor BEDs are shown in blue (column 3). The α/βeq values making the liver dose constraints
(columns 4 and 5) corresponding to the same tumor BED level equivalent and the equivalent liver BEDeq values
are displayed in red (columns 6 and 7). 15-fraction liver mean dose tolerances calculated from the 5-fraction
values using α/β = 4 Gy and the traditional BED formulation are in yellow (column 8), whereas the values
calculated by taking into account the dose shape differences are in cyan (last column).
Prescription dosea Tumor BEDb Used constraintsa α/βeqc BEDeqd Calculated 15 fx constraintsa
N = 5 N = 15 N = 5 N = 15 W/o shape With shape
50 67.5 100/97.88 13 22 0.17 211.4 16.77 20.91
45 58.05 85.5/80.52 15 24 0.74 76.36 19.75 24.70
40 N/A 72/N/A 15 N/A N/A N/A 19.75 24.70
35 45 59.5/58.5 15.5 24 1.14 57.82 20.51 25.65
30 37.5 48/46.88 16 27 0.24 232.6 21.26 26.61
27.5 N/A 42.63/N/A 17 N/A N/A N/A 22.79 28.53
a Physical dose values are in units of Gy.
, b BED values are calculated using α/βT = 10Gy, and are displayed as 5 fraction BED/15 fraction BEDs in Gy10 units.
, c α/β values displayed in units of Gy.
, d Equivalent BED values displayed in units of α/βeq , i.e. the α/β that makes the liver mean dose constraints BED
equivalent using the simple BED formula (Equation 2).
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(a) Dose distribution in the proton
plan.
(b) Dose distribution in the photon
plan (dose scaled to the same mean
liver dose as in the proton plan).
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Figure 3. Difference between proton and photon dose distribution for a liver patient. The photon
distribution was scaled to the same mean liver dose as in the proton plan, thus has significantly lower
GTV dose.
The average dose shape factor of the photon plans for the patients treated with 15 and 5 fractions
is ϕ15photon = 1.80 and ϕ5photon = 2.49, respectively. Using these values in Equation 7 to extrapolate the
5-fraction doses to 15 fractions (i.e. ϕref = ϕ5photon, ϕnew = ϕ15photon, Nref = 5 and Nnew = 15) results in
the doses shown in cyan in Table I, corresponding far better to the actual mean dose tolerances (within
0.3 Gy to 1.6 Gy).
3.3 Calculating Iso-Effective Mean Doses in New Modalities (Case 2)
3.3.1 Detailed Analysis of a Selected Patient
We present a detailed analysis of a patient where the difference between the proton and photon plans
was significant. The patient received proton treatment delivering DGTVnew = 50.4 Gy in 5 fractions to the
target volume, and Dnew = 12 Gy mean dose to the healthy liver. The corresponding dose distribution
is plotted in Figure 3a, the DVHs in Figure 3c. 60% of the liver was completely spared, whereas the
part close to the target received the full prescription dose. The relative liver dose is therefore low,
Dnew/D
GTV
new = 0.239, while the dose variance is high, var (Dnew) = 370 Gy2. Consequently the dose
shape factor is relatively large, ϕnew = 3.561.
The dose distribution in the (9 field) photon plan - that is scaled to the same mean liver dose as the
proton plan - is shown in Figure 3b, with the corresponding DVHs in Figure 3c. No part of the healthy
liver is completely spared, hence the relative dose is higher than in the proton plan, Dref/DGTVref = 0.328,
but the dose variance is smaller, var (Dref) = 105.4 Gy2. Consequently, the dose shape factor is smaller,
ϕref = 1.730 (for details on why proton plans generally have higher ϕ, see Section 1.2 of the SM).
Due to the shape difference, the same 12 Gy mean liver dose leads to significantly different mean
BEDs of 37.64 Gy4 for protons and 24.46 Gy4 for photons (α/βLiver = 4 Gy). Equation 6 reveals that
the proton plan is mean BED equivalent to a photon plan with a mean dose of 15.87 Gy, more than 30%
higher than 12 Gy. Conversely, if the proton plan was scaled to have identical mean BED to its photon
counterpart, the proton mean dose would be 9.24 Gy, 23% lower than 12 Gy. Hence, while protons allow
a dose escalation of 35% (i.e. a target mean dose of 50.4 Gy vs. 36.9 Gy with photons, see Figure 3c) by
matching the liver mean physical dose levels in the 2 modalities, this reduces to only 5% (proton target
dose of 38.6 Gy) when matching the mean BEDs.
3.3.2 Quantifying the Effects of Shape Difference
Figure 4 highlights the effects of the dose shape factor when iso-effective mean doses are calculated in
different modalities. Figure 4a shows the additional dose ∆D = Dref − Dnew in a reference modality
(with ϕref = 2, typical for IMRT) as a function of the shape difference ∆ϕ = ϕnew − ϕref between two
modalities for Nref = Nnew = 5 and different Dnew values. The additional dose increases both with the
difference in the spatial distribution ∆ϕ and with the mean dose Dnew in the new modality, whereas
9
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Figure 4. Dose effects of shape differences.
it decreases with the reference dose shape factor ϕref. The dose difference can get substantial for large
shape differences: e.g. for a shape difference of ∆ϕ = 3, a 5-fraction mean dose of 17 Gy in the new
modality is equivalent to a mean dose of 25 Gy in the reference modality, representing a +50% increase.
To quantify effects for clinical treatment plans, proton mean liver doses Dnew (with dose shape
factor ϕnew) were converted to mean BED equivalent photon mean doses Dref = Dnew + ∆D (with dose
shape factor ϕref) for all 24 patients, using the clinically delivered number of fractions for Nnew = Nref.
Figure 4b displays the resulting additional mean dose ∆D relative to the proton dose as a function of the
shape difference ∆ϕ = ϕnew − ϕref. Generally, higher dose shape differences lead to higher relative dose
differences, reaching 30-40% (in agreement with the theoretical results shown in Figure 4a). In absolute
terms, the mean BED equivalent photon doses are 1 Gy-4 Gy higher than the proton doses (Figure 4c).
3.4 Potential Dangers of Neglecting the Shape Effect (Case 3)
To study whether the additional dose due to shape differences can be potentially unsafe, Figure 5 displays
the mean BED equivalent 35-fraction photon mean doses (i.e. the results of Equation 6) vs. the simple
BED equivalent mean doses (i.e. the results of Equation 3). When the traditional BED formula is
used (Equation 2), all 35-fraction doses are below the 30 Gy liver tolerance [5, 31]. When the proton-
photon shape differences are accounted for (Equation 6) the mean dose is above 30 Gy in two cases (for
a discussion of the 30 Gy tolerance see Section 3 of the SM.).
3.5 Dose Escalation Potential of Proton Therapy (Case 4)
The ratio of the proton/scaled photon GTV doses - having identical gEUBED values for the healthy
liver according to Equation 10 - averaged over the 24 patients can be seen in Figure 6 for three different
α/β ratios and a range of volume parameters n ∈ [0, 1.2]. There are three findings:
• When 0 < n < 0.6, photon plans are generally better based on the physical dose, which is a
result of penalizing the larger high dose region of proton plans in the gEUD calculations. The only
exception is n = 0 (when only the maximum point dose in the healthy liver matters), primarily
caused by the slightly better homogeneity of proton plans in the GTV (see Figure 3c), typically
leading to higher average GTV doses for the same maximum point dose.
• For n > 0.6, protons are clearly better in terms of physical dose, as the low dose bath of photon
treatments starts to limit the GTV dose for a given gEUD value. For n = 1 on average a 25% dose
escalation potential can be observed for the same liver mean physical dose, well corresponding to
the 35% dose escalation found for the patient in Section 3.3.1 (case 2).
• Most importantly, adjusting for fractionation (α/β < ∞) significantly influences the achievable
benefit of protons. Except for small volume parameters (n ≈ 0), photons remain generally better
10
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Figure 5. Mean BED equivalent 35-fraction photon mean doses versus simple BED equivalent 35-fraction
mean doses.
till around n ≈ 0.6 (also see Figure 8 in Section C). For higher volume parameters (n > 0.6)
proton plans become better, but the BED adjustment increasingly penalizes them - mainly due to
their high dose region - decreasing their benefits. For the hypofractionated, clinical proton plans
(Figure 6a) we only see a 5% average dose escalation potential for n = 1 with α/β = 4 Gy (vs.
25% based on physical dose), increasing to 10% (vs. 35%) for n = 1.1 (the value previously found
for liver in [35]). For standard fractionation (Figure 6b) the degradation is less substantial, but is
still significant, only allowing for 15%/20% higher target doses with protons for n = 1/1.1 (instead
of 25%/35%). For a more detailed discussion of how the method of incorporating RBE affects the
dose escalation potential, see Section C.
4 Discussion
Regarding the Dose Shape Effects The dose shape factor has an opposite effect when deriving
doses for less and more fractions (Figure 2a). The truly mean BED equivalent doses are always lower
than what the traditional BED formalism (Equation 2) suggests when deriving doses for more hypofrac-
tionated schedules. Hence the standard BED equation leads to potentially unsafe, higher dose tolerances
than intended. Conversely, neglecting the dose shape factor when calculating the equivalent of hypofrac-
tionated mean doses in traditional fractionation schemes results in lower values than what is mean BED
equivalent. Therefore the simple BED formalism underestimates the effects of mean doses in hypofrac-
tionated schedules (Section 1.3 of the SM provides a mathematical proof of this duality).
Mean doses in plans with high dose variance could be mean BED equivalent to vastly (50%) higher
mean doses in less inhomogeneous plans (Figure 4a). Clinical treatment plans indeed exhibit such
sizable dose differences (Figures 4b-4c). Therefore, applying mean dose tolerances established for one
modality on-to-one to another with significantly more inhomogeneous dose distribution should be done
with caution, as this may lead to dose constraints that are too high. Instead, it is better to establish
dose tolerances according to Equation 7 by taking into account the (typical) differences between the dose
distributions of the two modalities.
The shape effect is especially important when the organ in question is the dose limiting structure,
so that its mean dose is close to its tolerance. For example, this is the case for liver tumors treated
in a dose escalation protocol where the liver mean dose meets the constraint in order to maximize the
11
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Figure 6. Dose escalation potential of protons vs. photons for equivalent gEUD based NTCP values with
various volume parameters n and fractionation sensitivities α/β.
prescription dose [26]. If a mean dose constraint was derived from patients treated with photon beams,
and the patient is treated with proton beams to the maximally allowed mean dose, the proton treatment
will typically violate the constraint in terms of mean BED. In our patient cohort on average protons
allowed for 25% dose escalation compared to photons for the same physical liver mean dose (as shown
in Figure 6). When dose escalation is instead performed based on mean liver BED, protons allowed for
only marginally (≈ 5%) higher prescription doses. Although this degradation of proton dose escalation
potential is less severe if standard fractionation is assumed for the plans (N = 35 fractions, 70 Gy proton
target dose with 2 Gy/fx), it was still significant, only allowing for ≈ 15% higher proton doses.
Regarding Mean BED Tolerances Our results are not specific for mean doses. As Figure 6 (and
Figure 8) highlight the dose escalation potential of proton therapy is significantly decreased for a wide
range of volume parameters (n > 0.6) when using a gEUD based NTCP model taking into account
fractionation. Hence while there is considerable uncertainty regarding the dose-volume effects in the
liver (and in other OARs in general), regardless of what the exact value of volume parameter is, the
dose shape, and specifically the larger margins of proton dose distributions compared to photon dose
distributions have an important effect on tolerances. These larger high dose areas get emphasized when
adjusting for fractionation, and consequently result in higher NTCP values in general. Therefore, within
the validity of gEUD based NTCP models including fractionation effects, proton plans are indicated to
result in higher normal tissue complications than what could be expected purely from the physical dose
distribution.
As a result, the dose escalation potential of protons is substantially reduced if mean BED (or in
general gEUBED) rather than mean physical dose (or gEUD) is the relevant metric to limit toxicity.
Based on the outcome data from photon treatments, this may indeed be the case e.g. for the liver and
the lung [31, 36]. These works conclude that the volume parameter is close to n = 1 in these organs and
the mean of the fraction-size adjusted dose distribution - which is only different from the mean BED up
to patient-independent constant factor, see Equation 11 in Section A - correlates with organ damage. In
fact, the liver SBRT protocol of [37] already describes the clinical use of such a mean BED constraint,
since the authors employ an LKB model based dose escalation scheme with a volume parameter of
n = 0.97 to determine individualized prescription doses for given NTCP values (5%, 10% or 20%).
In general, hepatotoxicity data from the published literature is always difficult to compare, mainly
due to considerable variation across studies in patient population, treatment regimens, exact definition
of radiation induced liver disease (RILD), etc. Moreover, research specifically focusing on analysing
the outcomes from proton vs. photon radiation therapy for RILD is rare [38]. Thus, in the context of
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comparing protons and photons for liver SBRT in particular, it is not clear whether mean physical dose,
mean BED, or some other metric is the most relevant for tissue damage. Preliminary data from our own
institution suggests that liver function is better preserved in proton therapy than in photon therapy. A
mean dose/BED constraint may therefore underestimate proton’s advantage of avoiding the low dose
bath in a significant portion of the liver. If instead a DVH point for the low dose bath is the relevant
metric for example, the dose escalation potential of protons is substantially higher. A commonly used
constraint for the liver in SBRT protocols, the sparing of at least 700 cm3 of the healthy liver to less than
15 Gy in 3-6 fractions [23, 39] indeed suggests that this may be the case. Based on this metric, should a
proton plan deliver virtually no dose to at least 700 cm3 of the liver, its dose escalation potential would
be infinite.
Regarding Relative Biological Effectiveness and Margins Throughout the paper RBE effects
were taken into account by adjusting proton doses with RBEproton = 1.1. Therefore all presented and
plotted proton doses were the RBE adjusted doses Dproton = RBEprotonD˜proton and all BED calculations
were done subsequent to the RBE adjustment. This can be considered a simplified approach, but is
consistent with current clinical practice, where the proton RBE is assumed to be fraction-size indepen-
dent. Dale and Jones [34] introduced a modified BED formulation that allows for the incorporation of
RBE effects. The differences between the two formulations are discussed in details in Section C. The
main conclusion is that the presented theory can easily be generalized according to [34], and for protons
- having an RBE relatively close to unity - the exact method of accounting for RBE is only of minor
importance, with the Dale-Jones RBE methodology predicting 5-10% smaller effects than our constant
RBE model.
A central focus of the paper is to study the effects of the dose shape. Clearly, the shape of the dose
distribution is closely connected to the employed margins in the proton (and photon) plans. Margins in
turn strongly depend on the considered organ motion, motion mitigation techniques as well as the choice
of proton delivery method (passive scattering or pencil beam scanning). Since our patient cohort focused
on liver cases (having relatively large motion uncertainties) treated with passively scattered protons, and
these proton plans were compared to state-of-the-art IMRT, our results likely represent a worst case
scenario for protons. For treatment sites with less motion, where better immobilization and motion
mitigation methods can be applied (e.g. brain), effects will be smaller. Additionally, advances in on-line
proton range verification methods are expected to decrease proton planning margins, which will further
reduce the current disadvantage of protons, i.e. the irradiation of larger areas around target structures
with the prescription dose compared to photons.
Regarding the Context of Our Work The main novelty of our work is a practical, but consistent
methodology that allows the establishment of (primarily) mean dose tolerances in new fractionation
schemes and new treatment modalities, such that they are iso-toxic as assessed from NTCP models.
Essentially, we achieve this by building on established radiobiological models (BED, DVHs and gEUD)
to arrive to the formulation of the gEUBED. These concepts are all well known and have been vali-
dated in clinical practice. However, they mainly represent phenomenological descriptions reflecting the
experience with fractionation (for BED) and volume effects (for DVH and gEUD), rather than a de-
tailed understanding of the exact radiobiological mechanisms underlying organ damage. As any model,
they unavoidably have their limitations. For example, the accuracy of the BED model to high dose per
fraction values has been debated excessively for decades, without final resolution [40, 41]. Summarizing
three-dimensional dose distributions by DVHs disregards where the dose is deposited exactly, therefore
cannot account for varying radiation sensitivity within the organ or the relative importance of some
functional sub-units over others for overall organ function. gEUD is a completely empirical concept: the
volume parameter is derived purely from experience and there is no known radiobiological justification
behind its mathematical form. Since our work builds on these concepts instead of using first principles,
it necessarily inherits all their shortcomings as well. Simply put, our message is that - regardless of
the actual underlying radiobiology - the presented approach is useful for its the intended purpose: to
establish mean dose tolerances in a more meaningful way than currently possible, taking into account
fractionation, dose shape and possibly RBE (see Section C) effects.
Despite these limitations of our study (and the fact that it is an in-silico comparison for patients
for whom outcome data is not yet available), it well justifies a warning and discussion regarding the
13
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use of mean dose - and in general gEUD - constraints for proton therapy that were derived for photon
therapy. As first reported by [42], photon-derived normal tissue complication models may indeed be
relatively well applicable to proton therapy treatments as well. Though the derivation of proton specific
NTCP models is naturally expected to remain an active research area, until such models are obtained
and validated, only the currently available ones can be used (e.g. to guide patient selection eligible for
proton treatments [43]). These (fraction-size adjusted) gEUD based NTCP models indicate that proton
therapy’s dose escalation potential may be reduced for a wide range of volume parameters, especially for
treatment sites with significant organ motion requiring large margins, warranting caution when using
a physical dose based escalation strategy. Similar care should be taken when applying photon therapy
based physical dose constraints to proton treatments, as they may overestimate tolerable doses due to
the significantly different dose distributions.
5 Conclusions
When mean dose tolerances are chosen for new fractionation schemes or irradiation modalities the shape
of the dose distribution should be accounted for. The traditional BED formalism tends to overestimate
tolerances when they are calculated for more hypofractionated regimes. In addition, mean tolerance
values - and gEUD tolerances in general - established for one modality cannot necessarily be applied
to other modalities having drastically different dose distributions. The formalism introduced in this
paper allows the incorporation of the spatial dose distribution into BED based estimation of mean dose
constraints, which can help alleviating these issues.
A Compatibility of Mean BED Equivalent and Iso-NTCP Based
Derivation of Mean Dose Constraints
Let us suppose we have an organ that receives a dose distribution D = (D1, ..., DM ) in N fractions
(M is the number of voxels). To calculate the associated NTCP value, most models rely on using
the generalized Equivalent Uniform Dose (the popular Lyman-Kutcher-Burman (LKB) approach also
belongs to this category, see Section B). When using any gEUD based NTCP model with a fractionation
component (as in [44, 36, 45, 46, 47, 31]) the following three steps are made [48, 18]:
• First, the doses are adjusted for fraction size, i.e. a dose distribution is calculated which - if given
in uniform fractional doses fs in each voxel - is BED equivalent to the original dose. This dose in
voxel i is
Dadj,i = Di
1 + Di
Nα/β
1 + fs
α/β
= BEDi
1 + fs
α/β
. (11)
[49] appropriately calls Equation 11 the "Fraction-size Equivalent Dose" and [50] refers to it as
"Equieffective Dose". If the fraction size is fs = 2 Gy/fraction Equation 11 is the well-known
Normalized Total Dose (NTD) [21, 51, 52] or Equivalent Dose delivered in 2 Gy fractions (EQD2).
• Next, using the fraction size adjusted dose distribution, the generalized Equivalent Uniform Dose
is calculated for a chosen volume parameter n [2] as
gEUDn (Dadj) =
(
1
M
M∑
i=1
D
1/n
adj,i
)n
=
 1M
M∑
i=1
 BEDi
1 + fs
α/β

1/n
n
=
(
1
M
M∑
i=1
(BEDi)1/n
)n
1 + fs
α/β
= gEUDn (BED (D, N, α/β))
1 + fs
α/β
= gEUBEDn (D, N, α/β)
1 + fs
α/β
. (12)
14
Page 14 of 23AUTHOR SUBMITTED MANUSCRIPT - PMB-106334.R1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60 Ac
ce
pte
d M
nu
cri
pt
We used the notation gEUBEDn (D, N, α/β) to signal a gEUDn (BED (D, N, α/β)) calculation
based on the BED distribution BED (D, N, α/β) = (BED1,BED2, ...,BEDM ), corresponding to
giving a dose distribution D in N fractions to an organ with fractionation sensitivity α/β (as
opposed to a gEUDn (D) calculation based on the physical dose distribution D directly). Sim-
ply stated, Equation 12 means that if we adjust for fractionation, the gEUD in an organ is a
constant factor times the "generalized Equivalent Uniform BED" [33]. This constant factor is
1/ (1 + fs/α/β), only depending on the chosen fraction size fs and the α/β ratio. In the lit-
erature Equation 12 has also been called the "modified Equivalent Uniform Dose" [53] and the
"radiobiologically corrected gEUD" [18].
• Last, normal tissue complication probability is calculated as
NTCP = h(gEUDn (Dadj)) =
1
1 +
(
TD50
gEUDn (Dadj)
)γ50 (13)
where the given logistic function in Equation 13 is only one possibility, in general there are several
possible forms for h (gEUDn (Dadj)).
Under this approximation two dose distributionsDref in Nref fractions andDnew in Nnew fractions will
be iso-effective if they lead to the same NTCP given by Equation 13. However, for a chosen NTCP model
(e.g. for fixed TD50 and γ50 parameters in a logistic model) this equivalence simply requires that after
adjusting for fractionation the two dose distributions give identical gEUDs according to Equation 12.
Consequently, if the same fraction size fs is used to adjust doses for fraction size, the equivalence further
simplifies to the equivalence of the "generalized Equivalent Uniform BEDs", i.e. to
gEUBEDn (Dref, Nref, α/β) = gEUBEDn (Dnew, Nnew, α/β) ,
which for a parallel structure (n = 1) leads to Equation 6. Hence our mean BED equivalent derivation
for a mean dose tolerance Dmean in a new fractionation scheme with Nnew number of fractions is simply
a special case of requiring the generalized EUD based NTCP values of the new and the reference dose
distributions to be identical for a parallel structure.
B The Dependence of the Lyman-Kutcher-Burman (LKB) NTCP
Model on the gEUD
In [54] it is proven that "the EUD for an OAR calculated by the generalized Niemierko formula yields a
dose which, if applied uniformly to the entire volume of the OAR, would result in the same NCTP as the
effective volume Kytcher-Burman DVH reduction algorithm, calculated for any reference dose." Essen-
tially the authors of [54] have already shown that the classic LKB model of NTCP can be reformulated
to depend on the gEUDn, furthermore [55] also highlights it, but for clarity this is explicitly pointed out
here.
In the Lyman model [56] the NTCP for a uniform irradiation of a fraction v = V/Vref of an organ
to dose D depends on a parameter
u = D − TD50(v)
m · TD50(v) ,
where TD50(v) = TD50(1)·v−n and TD50(1) are the partial-volume-dependent and whole organ doses for
50% complication probability andm characterizes the steepness of the dose response. For inhomogeneous
organ irradiation the Kutcher-Burman volume reduction is used [29], resulting in the effective volume
veff =
M∑
j=1
vj
(
Dj
Dref
) 1
n
,
where vj is the relative volume of element j (
∑M
j=1 vj = 1) receiving a normalized dose Dj/Dref for a
reference dose Dref . The assumption is that irradiation a veff fractional volume of the organ with dose
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Dref would result in the same complication probability as the inhomogeneous irradiation. Correspond-
ingly, the final NTCP value in the LKB model depends on
u = Dref − TD50(veff )
m · TD50(veff ) .
However, this dependence can be reformulated as
u =
Dref − TD50(1)
vneff
m · TD50(1)
vneff
=
Dref − TD50(1) M∑
j=1
vj
(
Dj
Dref
) 1
n

n
m · TD50(1) M∑
j=1
vj
(
Dj
Dref
) 1
n

n
=
1− TD50(1) M∑
j=1
vjD
1
n
j

n
m · TD50(1) M∑
j=1
vjD
1
n
j

n
=
1− TD50(1)gEUDn (D)
m · TD50(1)gEUDn (D)
= gEUDn (D)− TD50 (1)
m · TD50(1) ,
which concludes our proof that the LKB model is an NTCP model directly depending on the generalized
Equivalent Uniform Dose as defined by [2].
C Inclusion of Relative Biological Effectiveness
Throughout the paper we included RBE effects by using RBEproton = 1.1 and consequently presenting
all proton physical doses as the RBE corrected doses Dproton = RBEprotonD˜proton. All BED calculations
were done subsequent to taking into account the RBE effect, thus the derived proton doses for new frac-
tionation regiments and new dose shape factors were directly the RBE corrected doses. This is consistent
with current clinical practice, where the proton RBE is assumed to be fraction-size independent. In [34]
a modified BED formulation is presented that directly incorporates RBE effects into the BED model.
This modified BED formulation reads
BED = D
(
RBE + D
Nα/βL
)
,
where α/βL is the α/β ratio representative for low Linear Energy Transfer (LET) radiation (practically
photons, simply denoted as α/β from this point), and D and RBE are the (non-RBE adjusted) dose and
the intrinsic RBE value for the given radiation (which can be both low and high LET). All our results can
be generalized according to this Dale-Jones RBE model, and this appendix presents both these general
formulas, as well as the sensitivity of our results to this different formulation.
C.1 Generalized BED formulas
Equating the BEDs for two regimens with different radiations yields the general counterpart of Equation 2
as
Dnew
(
RBEnew +
Dnew
Nnewα/β
)
= Dref
(
RBEref +
Dref
Nrefα/β
)
. (14)
The solution of Equation 14 for the new dose Dnew (c.f. Equation 3) is
Dnew =
1
2
[√
(Nnewα/βRBEnew)2 + 4Dref
(
Nnewα/βRBEref +Dref
Nnew
Nref
)
−Nnewα/βRBEnew
]
. (15)
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The mean BED is a straightforward extension of Equation 4 with the RBE effect leading to
BEDmean = Dmean
(
RBE + Dmean
Nα/β
ϕ
)
. (16)
Therefore, a new mean dose tolerance Dmean can be obtained in a mean BED equivalent manner by
solving
Dnew
(
RBEnew +
Dnew
Nnewα/β
ϕnew
)
= Dref
(
RBEref +
Dref
Nrefα/β
ϕref
)
(17)
instead of Equation 6. The solution (c.f. Equation 7) is
Dnew =
1
2
√(Nnewα/βRBEnew
ϕnew
)2
+ 4Dref
(
Nnewα/βRBEref
ϕnew
+Dref
ϕref
ϕnew
Nnew
Nref
)
− Nnewα/βRBEnew
ϕnew
 .
(18)
Last, the formula for the generalized Equivalent Uniform BED with the RBE being taken into account
(c.f. Equation 9) reads
gEUBEDn (D, N, α/β,RBE) =
1
M
[
M∑
i=1
(
Di
(
RBE + Di
Nα/β
))1/n]n
. (19)
Thus, for iso-toxic dose escalation, i.e. to calculate how a dose distribution Dnew (with a radiation type
having an RBE value RBEnew) can be scaled to a distribution f ·Dnew such that it leads to the same
NTCP as the reference distribution Dref (with an RBE value of RBEref),
gEUBEDn (f ·Dnew, Nnew, α/β,RBEnew) = gEUBEDn (Dref, Nref, α/β,RBEref )
has to hold, leading to the general counterpart of Equation 10, reading 1
M
M∑
i=1
(
f ·Dnew,i
(
RBEnew +
f ·Dnew,i
Nnewα/β
))1/nn =
 1
M
M∑
i=1
(
Dref,i
(
RBEref +
Dref,i
Nrefα/β
))1/nn .
(20)
This more consistent formulation decreases the BED values for all proton plans. In our original
formulation, the proton physical doses Dproton = RBEprotonD˜proton were used directly in the BED
equation, leading to BED = Dproton
(
1 + Dproton
Nα/β
)
. In contrast, the more consistent formulation reads
D˜proton
(
RBEproton + D˜proton
Nα/β
)
= Dproton
(
1 + Dproton
Nα/βRBE2proton
)
, obviously smaller for RBE values
above 1. The relative BED difference (compared to our original formulation) is
∆BED
BED = −
RBE2proton − 1
RBE2proton
1
1 + Nα/β
Dproton
. (21)
For RBEproton = 1.1 this translates to a maximum difference of −17.3% (for Dproton/N = ∞), and it
decreases with decreasing dose per fraction size (e.g. for Dproton/N = 2 Gy and α/β = 3 Gy we find
∆BED/BED = −6.9%).
C.2 Sensitivity to Accounting for RBE
To test the sensitivity of our results to the different incorporation of the RBE all calculations have been
done using both approaches. Figure 7 shows the general counterparts of the most important figures
regarding the shape and fractionation effects, displaying both the results of our original formulation
(labeled as "Constant RBE" in blue) as well as the formulation of [34] ("Dale-Jones RBE" in red).
As expected, the more consistent methodology decreases effects. Nevertheless, the differences are small
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(a) Mean doses in 35 fractions that
are equivalent with the given pro-
ton doses in 5/15 fractions, with
(y-axis) and without (x-axis) tak-
ing into account the dose shape (c.f.
Figure 2b).
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mean dose (c.f. Figure 4c).
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Figure 7. The influence of the method of taking into account the RBE of protons. The Dale-Jones RBE
model predicts slightly smaller effects than the constant RBE method, however the differences do not
alter our main conclusions.
(around 5-10%), and our main conclusions remain valid: neglecting the shape effect when calculating iso-
effective doses in new fractionation schemes (Figure 7a) and new modalities (Figure 7b) underestimates
their biological effects, and there are situations where neglecting the dose shape effect leads to significantly
lower doses than are iso-effective (Figure 7c).
The effect of the proton RBE incorporation on the dose escalation potential of protons compared to
photons is also relatively small (see Figure 8). All physical dose based results (α/β =∞) naturally remain
unchanged, whereas the BED based calculations (α/β < ∞) yield around 5-10% higher proton/photon
GTV dose ratios than our original formulation (compare with Figure 6). This is a straightforward
consequence of the different handling of the RBE: since the Dale-Jones method leads to lower BED values
for protons, photon doses - for which the 2 formulations are identical - can be scaled less, leading to
higher proton/photon target dose ratios. For a mean BED constraint (n = 1) with our hypofractionated
(5/15 fraction) treatments adjusting for fractionation decreases protons’ dose escalation potential to only
12% compared to the 25% based on physical dose, and for n = 1.1 [35] to only 17% compared to 35%
(c.f. our 5% and 10% estimates based on Figure 6a). Just as is the case in Section 3.5, the differences
somewhat decrease when standard fractionation is assumed (Figure 8b). Understandably, the biggest
contrast between the two formulations is seen for n ∈ [0, 0.6], since for small volume parameters more
and more the highest dose values matter (i.e. the voxels having the highest doses and dose per fraction
values), and the BED difference is increasing with the dose per fraction (in accordance with Equation 21).
In this region the BED adjustment including RBE predicts higher dose escalation potential than based
on physical dose, as the degradation due to accounting for fractionation is counterbalanced by the more
beneficial RBE effect. For n > 0.6 the fractionation effect becomes dominant (as all voxels become
increasingly important), and though the Dale-Jones RBE approach does predict a higher dose escalation
potential for protons than our constant RBE approach, this potential is still substantially lower than is
expected based on physical dose.
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(a) Reference: hypofractionated (5/15 fraction), clini-
cally delivered proton plans (c.f. Figure 6a).
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(b) Reference: scaled proton plans assuming standard
fractionation (70 Gy GTV dose with 2 Gy/fx, 35 frac-
tions, c.f. Figure 6b).
Figure 8. Dose escalation potential of protons vs. photons for equivalent gEUD based NTCP values
with various volume parameters n and fractionation sensitivities α/β, with the Dale-Jones method of
accounting for RBE based on [34].
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